Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04762953 · ClinicalTrials.gov registry record · Phase 2
Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis
A Phase 2 study of Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, sponsored by University of California, Irvine.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT04762953 is a Phase 2 study of Gastric Cancer and Gastroesophageal Junction Adenocarcinoma that is active but no longer recruiting, run by University of California, Irvine. The registered enrollment target is 40 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04762953, a Phase 2 study of Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, is active but no longer recruiting, sponsored by University of California, Irvine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II clinical trial assessing the safety and efficacy of sequential systemic and intraperitoneal (IP) chemotherapy in patients with primary gastric/gastroesophageal junction cancer with cytology positive peritoneal lavage and/or peritoneal carcinomatosis.
Conditions Studied
Interventions
- DRUG Fluorouracil
- DRUG Leucovorin
- DRUG Paclitaxel
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center, University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04762953
The ClinicalTrials.gov registry entry for NCT04762953 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (87% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which Fluorouracil is the first listed.
NCT04762953 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04762953 about?
NCT04762953 is a clinical study titled "Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis". This is a phase II clinical trial assessing the safety and efficacy of sequential systemic and intraperitoneal (IP) chemotherapy in patients with primary gastric/gastroesophageal junction cancer with cytology positive peritoneal lavage and/or peritoneal carcinomatosis.
What is the current status of trial NCT04762953?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-02-18. Estimated completion is 2026-12.
What conditions does trial NCT04762953 study?
This clinical trial studies the following conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis.
What interventions are being tested in trial NCT04762953?
The interventions under investigation include: Fluorouracil (DRUG), Leucovorin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT04762953?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04762953 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.